Prix Kymera Therapeutics Inc (KYMR)

Kymera Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of small molecule therapeutics that degrade disease-causing proteins. The company is headquartered in Watertown, Massachusetts and currently employs 225 full-time employees. The company went IPO on 2020-08-21. The firm is focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system with a primary focus on immunology. The firm's targeted protein degradation (TPD) platform, which is a small molecule therapeutic modality that engages the body’s natural cellular recycling system to selectively eliminate disease-causing proteins. Its immunology programs target STAT6, IRF5 and IRAK4, each of which addresses targets within validated pathways, providing the opportunity to treat a broad range of diseases. The company is developing KT-621 as part of its STAT6 program, which is being evaluated in a Phase I clinical trial in healthy volunteers. The company is developing KT-579, which is an investigational, first-in-class, oral degrader of IRF5, a genetically validated transcription factor and a master regulator of immunity.